Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Luteolin and fisetin suppress oxidative stress by modulating sirtuins and forkhead box O3a expression under in vitro diabetic conditions

  • Kim, Arang (Department of Food and Nutrition, Chonnam National University) ;
  • Lee, Wooje (National Research Center for Dementia, Chosun University) ;
  • Yun, Jung-Mi (Department of Food and Nutrition, Chonnam National University)
  • Received : 2017.07.17
  • Accepted : 2017.08.31
  • Published : 2017.10.02
Download PDF
⟨ Previous Next ⟩

Abstract

BACKGROUND/OBJECTIVE: Chronic hyperglycemia induces oxidative stress via accumulation of reactive oxygen species (ROS) and contributes to diabetic complications. Hyperglycemia induces mitochondrial superoxide anion production through the increased activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. This study aimed to determine whether fisetin and luteolin treatments suppress the oxidative stress by modulating the expression of sirtuins (SIRTs) and forkhead box O3a (FOXO3a) under hyperglycemic conditions in human monocytes. MATERIALS/METHODS: Human monocytic cells (THP-1) were cultured under osmotic control (14.5 mmol/L mannitol), normoglycemic (NG, 5.5 mmol/L glucose), or hyperglycemic (HG, 20 mmol/L glucose) conditions, in the absence or presence of fisetin and luteolin for 48 h. To determine the effect of fisetin and luteolin treatments on high glucose-induced oxidative stress, western blotting and intracellular staining were performed. RESULTS: Hyperglycemic conditions increased the ROS production, as compared to normoglycemic condition. However, fisetin and luteolin treatments inhibited ROS production under hyperglycemia. To obtain further insight into ROS production in hyperglycemic conditions, evaluation of p47phox expression revealed that fisetin and luteolin treatments inhibited p47phox expression under hyperglycemic conditions. Conversely, the expression levels of SIRT1, SIRT3, SIRT6, and FOXO3a were decreased under high glucose conditions compared to normal glucose conditions, but exposure to fisetin and luteolin induced the expression of SIRT1, SIRT3, SIRT6, and FOXO3a. The above findings suggest that fisetin and luteolin inhibited high glucose-induced ROS production in monocytes through the activation of SIRTs and FOXO3a. CONCLUSIONS: The results of our study supports current researches that state fisetin and luteolin as potential agents for the development of novel strategies for diabetes.

Keywords

References

  1. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137-88. https://doi.org/10.1152/physrev.00045.2011
  2. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76. https://doi.org/10.2337/diacare.28.1.164
  3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20. https://doi.org/10.1038/414813a
  4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25. https://doi.org/10.2337/diabetes.54.6.1615
  5. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70. https://doi.org/10.1161/CIRCRESAHA.110.223545
  6. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Elbim C. Phagocyte NADPH oxidase: a multicomponent enzyme essential for host defenses. Arch Immunol Ther Exp (Warsz) 2005;53:199-206.
  7. Venugopal SK, Devaraj S, Yang T, Jialal I. Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes 2002;51:3049-54. https://doi.org/10.2337/diabetes.51.10.3049
  8. Yun JM, Chien A, Jialal I, Devaraj S. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 2012;23:699-705. https://doi.org/10.1016/j.jnutbio.2011.03.012
  9. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012;13:225-38. https://doi.org/10.1038/nrn3209
  10. Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 2013;37:315-25. https://doi.org/10.4093/dmj.2013.37.5.315
  11. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 2013;14:83-97.
  12. Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008;27:2320-36. https://doi.org/10.1038/onc.2008.25
  13. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, Motoyama N. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 2005;16:237-43.
  14. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011-5. https://doi.org/10.1126/science.1094637
  15. Rathee P, Chaudhary H, Rathee S, Rathee D, Kumar V, Kohli K. Mechanism of action of flavonoids as anti-inflammatory agents: a review. Inflamm Allergy Drug Targets 2009;8:229-35. https://doi.org/10.2174/187152809788681029
  16. Peterson JJ, Dwyer JT, Jacques PF, McCullough ML. Associations between flavonoids and cardiovascular disease incidence or mortality in European and US populations. Nutr Rev 2012;70:491-508. https://doi.org/10.1111/j.1753-4887.2012.00508.x
  17. Nicolle E, Souard F, Faure P, Boumendjel A. Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship. Curr Med Chem 2011;18:2661-72. https://doi.org/10.2174/092986711795933777
  18. Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H, Tian B. Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 2011;108:84-93. https://doi.org/10.1111/j.1742-7843.2010.00613.x
  19. Currais A, Prior M, Dargusch R, Armando A, Ehren J, Schubert D, Quehenberger O, Maher P. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell 2014;13:379-90. https://doi.org/10.1111/acel.12185
  20. Kwak S, Ku SK, Bae JS. Fisetin inhibits high-glucose-induced vascular inflammation in vitro and in vivo. Inflamm Res 2014;63:779-87. https://doi.org/10.1007/s00011-014-0750-4
  21. Xia F, Wang C, Jin Y, Liu Q, Meng Q, Liu K, Sun H. Luteolin protects HUVECs from THF-${\alpha}$-induced oxidative stress and inflammation via its effects on the Nox4/ROS-NF-${\kappa}B$ and MAPK pathways. J Atheroscler Thromb 2014;21:768-83. https://doi.org/10.5551/jat.23697
  22. Seelinger G, Merfort I, Schempp CM. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 2008;74:1667-77. https://doi.org/10.1055/s-0028-1088314
  23. Zang Y, Igarashi K, Li Y. Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-A(y) mice. Biosci Biotechnol Biochem 2016;80:1580-6. https://doi.org/10.1080/09168451.2015.1116928
  24. Kim HJ, Kim SH, Yun JM. Fisetin inhibits hyperglycemia-induced proinflammatory cytokine production by epigenetic mechanisms. Evid Based Complement Alternat Med 2012;2012:639469.
  25. Kim HJ, Lee W, Yun JM. Luteolin inhibits hyperglycemia-induced proinflammatory cytokine production and its epigenetic mechanism in human monocytes. Phytother Res 2014;28:1383-91. https://doi.org/10.1002/ptr.5141
  26. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut- Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 2009;41:217-25. https://doi.org/10.3858/emm.2009.41.4.058
  27. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol 2009;5:367-73. https://doi.org/10.1038/nrendo.2009.101
  28. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, Prolla TA. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010;143:802-12. https://doi.org/10.1016/j.cell.2010.10.002
  29. Liao CY, Kennedy BK. SIRT6, oxidative stress, and aging. Cell Res 2016;26:143-4. https://doi.org/10.1038/cr.2016.8
  30. Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med 2013;63:222-34. https://doi.org/10.1016/j.freeradbiomed.2013.05.002

Cited by

  1. Silver Fir (Abies alba) Extracts Inhibit Enzymes Involved in Blood Glucose Management and Protect against Oxidative Stress in High Glucose Environment pp.1573-9104, 2019, https://doi.org/10.1007/s11130-018-0698-6
  2. Can luteolin be a therapeutic molecule for both colon cancer and diabetes? vol.18, pp.4, 2019, https://doi.org/10.1093/bfgp/ely036
  3. The plant flavonoid, fisetin alleviates cigarette smoke‐induced oxidative stress, and inflammation in Wistar rat lungs vol.43, pp.8, 2017, https://doi.org/10.1111/jfbc.12962
  4. Luteolin in the Management of Type 2 Diabetes Mellitus vol.7, pp.2, 2019, https://doi.org/10.12944/crnfsj.7.2.09
  5. Sirtuins as Important Factors in Pathological States and the Role of Their Molecular Activity Modulators vol.22, pp.2, 2021, https://doi.org/10.3390/ijms22020630
  6. Dietary Restriction and Oxidative Stress: Friends or Enemies? vol.34, pp.5, 2017, https://doi.org/10.1089/ars.2019.7959
  7. A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer’s Disease, Aging, Cancer, Inflammation, and Diabetes vol.22, pp.8, 2021, https://doi.org/10.3390/ijms22084180
  8. Plants Secondary Metabolites as Blood Glucose-Lowering Molecules vol.26, pp.14, 2017, https://doi.org/10.3390/molecules26144333
  9. Promising drug discovery strategies for sirtuin modulators: what lessons have we learnt? vol.16, pp.8, 2017, https://doi.org/10.1080/17460441.2021.1915980
  10. Inhibitory Effect of Fisetin on α-Glucosidase Activity: Kinetic and Molecular Docking Studies vol.26, pp.17, 2017, https://doi.org/10.3390/molecules26175306
  11. SIRT1-FOXOs activity regulates diabetic complications vol.175, pp.None, 2017, https://doi.org/10.1016/j.phrs.2021.106014